Related Experiment Video
Updated: Jun 2, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Effectiveness of interferon-beta therapy for recurrent glioblastoma: a case report
Satoshi Utsuki1, Hidehiro Oka, Yoshiteru Miyajima
1Department of Neurosurgery, Kitasato University, School of Medicine, Sagamihara, Kanagawa, Japan. utsuki@med.kitasato-u.ac.jp
Aims And Background:
Glioblastoma has a poor prognosis, with few therapeutic options if it recurs. We report a case in which we were able to inhibit the growth of a recurrent glioblastoma by weekly single-dose administration of interferon-beta.
Case Report:
A patient with recurrent glioblastoma after radiation and chemotherapy was treated with nimustine and interferon-beta. After 2 cycles of nimustine, the patient's leukocyte, neutrophil, and platelet counts showed grade 4 toxicity according to the National Cancer Institute's Common Toxicity Criteria. The patient was treated with a weekly single dose of interferon-beta at 6 x 10(6) IU. The tumor showed no remarkable changes after 18 months, and the patient's Karnofsky performance status remained at 50%.
Conclusions:
The administration of interferon-beta produced long-term control in one case of glioblastoma and may be an effective therapy.
